slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
The Global Hypercalcemia Treatment Market Analysis| Coherent Market Insights PowerPoint Presentation
Download Presentation
The Global Hypercalcemia Treatment Market Analysis| Coherent Market Insights

The Global Hypercalcemia Treatment Market Analysis| Coherent Market Insights

1 Vues Download Presentation
Télécharger la présentation

The Global Hypercalcemia Treatment Market Analysis| Coherent Market Insights

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services COVID-19 Impact Tracker

  2. HYPERCALCEMIA TREATMENT MARKET ANALYSIS HypercalcemiaTreatment Market,ByDrug Type (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate, Zoledronic, Acid), Calcitonin, Glucocorticoids, Denosumab, Calcimimetics), By Distribution Channel (Hospitals, Clinics, Independent Pharmacy & Drug Stores), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

  3. The global hypercalcemia treatment market is estimated to account for US$ 10,696.6 Mn in terms of value in 2018 and is expected to reach US$ 28,060.0 Mn by the end of 2028. Drivers • High incidence of hypercalcemia is a major factor boosting growth of the global hypercalcemia treatment market.Forinstance,inthe study,‘Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?’, published in the Journal of Clinical and Translational Endocrinology,inSeptember 2018, researchers found that 27.72% of the study patients suffered from hypocalcemia and 4.74% from hypercalcemia. Moreover, 585 cases of hypercalcemia were detected. • Moreover,increasingprevalence of cancer is also expected to aid in growth of the market. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

  4. Moreover, favorable reimbursement scenario is also expected to aid in growth of the market. Reimbursements enable lesser out-of-pocket costs of treatment for patients, despite having a low income eligibility.Forinstance, Amgen has a reimbursement policy on its XGEVA (denosumab injection), in which the company pays the out-of-pocket amount in excess of US$ 25 per dose; up to US$ 10,000 in assistance per calendar year. Approximately 70% of XGEVA patients with commercial or Medicare coverage incurred US$ 0 out-of-pocket cost due to favorable reimbursement policy offered by Amgen,Inc. • North America region held dominant position in the global hypercalcemia treatment market in 2018, accounting for 45.5% share in terms of value, followed by Europe.

  5. Market Opportunities • Product innovations in hypercalcemia drug types other than bisphosphonates is expected to offer lucrative growth opportunities for players in the global hypercalcemia treatment market.Bisphosphonateis the single largest product being utilized for hypercalcemiatreatment.Endusers have recognized the bisphosphonate therapy as effective.Still,theglobal hypercalcemia treatment market is yet to witness major product innovations in the product types of calcitonin, calcimimetics,andglucocorticoids. • Improving systems for recognizing hypercalcemia can aid in addressing common causes for delayed diagnosis and treatment of the disease,therebyaiding in growth of the market.Educatingpatients and providers about the consequences of untreated disease can also help in this regard.

  6. Bisphosphonates segment in the global hypercalcemia treatment market was valued at US$ 7,306.2 Mn in 2018 and is expected to reach US$ 19,798.3 Mn by 2027 at a CAGR of 11.7% during the forecast period.

  7. Market Trends • R&D in the treatment of hypercalcemia is augmenting growth of the market. For instance,inJuly 2019, researchers from AscendisPharma A/S, in their study, ‘Design and Preclinical Development of TransCon PTH, an Investigational Sustained?Release PTH Replacement Therapy for Hypoparathyroidism,’ reported that TransCon PTH can be used to normalize blood levels of calcium and phosphate. • Sarcoidosis,acomplex disease with no known cause, is linked with hypercalcemia.Thestudy,“Hypercalcemic pancreatitis a rare presentation of sarcoidosis: A case report,” published in the journal Medicine in January 2018, reported a sarcoidosis patient with pancreatitis — inflammation of the pancreas — and hypercalcemia.

  8. Competitive Section Major players operating in the global hypercalcemia treatment market include, Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and XOMA Corporation.

  9. Key Developments  Players in the market are focused on attending various conferences to expand their customer base.Forinstance, in October 2019, XOMA Corporation presented at the 2019 Cantor Fitzgerald Global Healthcare Conference held in New York.

  10. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference:

  11. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  12. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email:

  13. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter